A recent study has highlighted the risks and benefits associated with the administration of intermittent androgen deprivation therapy in patients with metastatic prostate cancer. Although there are improvements in many quality-of-life domains, these improvements must be carefully weighed against the potential harms of intermittent androgen deprivation therapy in this patient population.
